- Home
- SOC vs COAG Comparison
SOC vs COAG Comparison
Compare SOC & COAG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SOC | COAG |
|---|---|---|
| Founded | 2020 | N/A |
| Country | United States | United States |
| Employees | 200 | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.4B |
| IPO Year | N/A | 2026 |
Fundamental Metrics
Financial Performance| Metric | SOC | COAG |
|---|---|---|
| Price | $5.04 | $49.60 |
| Analyst Decision | Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $17.33 | N/A |
| AVG Volume (30 Days) | ★ 6.9M | 428.8K |
| Earning Date | 05-14-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $73.55 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.88 | $27.47 |
| 52 Week High | $29.81 | $53.61 |
Technical Indicators
Market Signals| Indicator | SOC | COAG |
|---|---|---|
| Relative Strength Index (RSI) | 46.36 | 60.52 |
| Support Level | $3.95 | $42.65 |
| Resistance Level | $5.33 | $51.50 |
| Average True Range (ATR) | 0.36 | 4.41 |
| MACD | 0.28 | -0.15 |
| Stochastic Oscillator | 71.84 | 69.31 |
Price Performance
Historical ComparisonAbout SOC Sable Offshore Corp.
Sable Offshore Corp is a Houston-based independent upstream company focused on developing the Santa Ynez Unit in federal waters offshore California. The company operates as one reportable oil and gas segment and is engaged in the acquisition, development, exploration, and production of oil and natural gas.
About COAG Hemab Therapeutics Holdings Inc. Common Stock
Hemab Therapeutics Holdings Inc is a clinical-stage biotechnology company developing therapies for the treatment of blood coagulation disorders. It focuses on discovering, developing, and commercializing treatments for conditions such as Glanzmann thrombasthenia, Factor VII deficiency, and von Willebrand disease. Its flagship candidate, sutacimig (HMB-001), is a bispecific antibody currently in clinical trials for the prophylactic treatment of Glanzmann thrombasthenia and Factor VII deficiency. The company has one operating segment, engaged in the research and development of prophylactic therapeutics for bleeding disorders.